Lisata Therapeutics (LSTA)

• Market cap: $18.6M
• 1 day: -3.2%
• 5 days: -1.4%
• 1 month: -16.21%
• 3 months: -15.54%
• 6 months: -10.92%
• Year to date: -40.62%
• 1 year: -27.15%
• 5 years: -92.68%
• 10 years: -99.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Employees: 26

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

23% more capital invested

Capital invested by funds: $1.84M [Q1] → $2.26M (+$417K) [Q2]

0.01% less ownership

Funds ownership: 9.09% [Q1] → 9.08% (-0.01%) [Q2]

5% less funds holding

Funds holding: 22 [Q1] → 21 (-1) [Q2]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15
• Avg. target: $24
• High target: $32

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis	$15	Buy Reiterated	21 Aug 2025
Brookline Capital Kemp Dolliver	$32	Buy Maintained	15 Jul 2025